Invezz is an independent platform with the goal of helping users achieve financial freedom. In order to fund our work, we partner with advertisers who compensate us for users that Invezz refers to their services. While our reviews and assessments of each product on the site are independent and unbiased, brands may pay to appear higher up our table rankings or place ads in specific areas of the site. The order in which products and services appear on Invezz does not represent an endorsement from us, and please be aware that there may be other platforms available to you than the products and services that appear on our website. Read more about how we make money >
Viatris Inc (NASDAQ:VTRS)
|Dividend Rate (ttm)||0.3273|
|Trading Day||Nov 29|
|Day's Range||Market Closed|
|52 Week Range||12.47 - 18.43|
Viatris Inc dividends
Viatris Inc has a market cap or net worth of $15.14 billion. The enterprise value is $37.77 billion.
Viatris Inc has 1.21 billion shares outstanding.
The trailing PE ratio is -7.8817 and the forward PE ratio is 3.4438. Viatris Inc's PEG ratio is 0.0182.
Stock Price Statistics
The stock price has decreased by -0.3163%. The beta is 0.8390, so Viatris Inc's price volatility has been lower than the market average.
In the last 12 months, Viatris Inc had revenue of $17.17 billion and earned $4.74 billion in profits. Earnings per share was $-1.71.
Viatris Inc. is a new kind of healthcare company, empowering people worldwide to live healthier at every stage of life.
It provides access to medicines, advance sustainable operations, develop innovative solutions and leverage its collective expertise to connect more people to more products and services through its one-of-a-kind Global Healthcare GatewayTM. Formed in November 2020through the combination of Mylan and Pfizer's Upjohn business, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories.
Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, a growing portfolio of biosimilars and a variety of over-the-counter consumer products. With a global workforce of approximately 45,000, Viatris is headquartered in the U.S., with global centers in Pittsburgh, Shanghaiand Hyderabad, India..